The federal government may ask all 14 judges on the U.S. Third Circuit Court of Appeals to review a three-judge panel’s unanimous January opinion upholding AstraZeneca, Novo Nordisk, and Sanofi’s restrictions on 340B pricing when their drugs are shipped to
…
The 340B program “is a really successful program and it hasn’t really cut the profits of the pharmaceutical companies dramatically,” U.S. Senate Majority Whip Dick Durbin (D-Ill.) said Friday during a visit to a Chicago-based community health center.
Durbin is
…
Pharmaceutical Research and Manufacturers of America asked a U.S. appeals court in St. Louis, Mo. last week to strike down Arkansas’s first-of-its-kind 340B contract pharmacy law, arguing that it intrudes on the 340B statute and frustrates Congress’ intent to limit
…
A federal district judge in Baltimore, Md., yesterday stayed the brand drug industry’s lawsuit challenging the December 2020 340B program administrative dispute resolution final rule.
Lawyers for Pharmaceutical Research and Manufacturers of America and U.S. Health and Human Services Secretary
…
Could ending the fights over limits on 340B contract pharmacy and encroachment on providers’ 340B savings hinge on hospitals accepting 340B reporting requirements? 340B Report Publisher and CEO Ted Slafsky raises that provocative question in his monthly column for Verity
…
National and state health center associations have filed amicus briefs in a lawsuit over California’s shift of Medicaid pharmacy benefits to Medicaid fee for service. They say the move will cost 340B providers in the state millions in savings needed
…
New research by drug industry contractor IQVIA questions whether claims identifiers can be used successfully to exclude 340B-purchased drugs from new Medicare drug inflation rebates or to protect manufacturers from paying both a new negotiated Medicare price and a 340B
…
America’s Essential Hospitals asked U.S. Health and Human Services Secretary Xavier Becerra late last week “to swiftly remedy five years of unlawful drug reimbursement cuts to 340B
hospitals under Medicare Part B.”
“These cuts, and a delay in recompensing hospitals for
…
U.S. Sen. Tammy Baldwin (D-Wis.), who has a long track record of support for 340B covered entities, is the new leader of a Senate Appropriations subcommittee with influence over 340B policy.
Baldwin announced yesterday she will serve as chair
…
Health care providers in the coming months may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and so-called “OTC monograph” drugs thanks to language tucked into the massive fiscal year 2023 federal spending bill signed into law
…
×
*Sign up for news summaries and alerts from 340B Report